SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Interferon-alpha; Interferons; Sunitinib

Criteria

Inclusion Criteria:

• Histologically confirmed renal cell carcinoma of clear cell histology with metastases

• Evidence of measurable disease by radiographic technique

• Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

• Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC

• History of or known brain metastases

• Serious acute or chronic illness or recent history of significant cardiac abnormality